MedDataX Logo

Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm

NCT ID: NCT00710255

Last Updated: 2016-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

8 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-10-31

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research is being conducted to help us better understand what causes exercise induced asthma. The investigators hypothesize that two types of chemicals, cysteinyl leukotrienes and adenosine, play an important role. The investigators will be measuring these chemicals in the exhaled breath of volunteers with exercise induced asthma as they undergo a test to mimic exercise induced asthma. The investigators will determine how the levels of these chemicals change in association with how lung function changes before, during and after an episode of exercise induced asthma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma, Exercise Induced

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Asthma Exercise induced bronchospasm Hyperpnea induced bronchospasm leukotrienes adenosine exhaled breath condensate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asthmatics

Asthmatics with exercise induced bronchospasm

Hyperpnea challenge

Intervention Type PROCEDURE

5 minutes of dry air hyperpnea to induce bronchospasm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyperpnea challenge

5 minutes of dry air hyperpnea to induce bronchospasm

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Physician diagnosed asthma
* Age 12-75 yrs
* FEV1 \> 70% predicted
* HIB response \> 10 %
* No smoking last 6 mo and \< 10 pack yrs
* No URI last 4 weeks
* No asthma exacerbation last 4 weks
* Able to withhold SABA \> 8 hrs and LABA \> 24 hrs

Exclusion Criteria

* Other lung disease
* Cardiac disease or other condition that would preclude safe participation, on theophylline or leukotriene modifiers
Minimum Eligible Age

12 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Vermont

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

David Kaminsky, MD

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David A. Kaminsky, MD

Role: PRINCIPAL_INVESTIGATOR

University of Vermont

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vermont Lung Center

Colchester, Vermont, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Merck IISP 32710

Identifier Type: -

Identifier Source: secondary_id

CHRMS 08-023

Identifier Type: -

Identifier Source: org_study_id